

Designation: F 2027 - 00^{€1}

Standard Guide for Characterization and Testing of Substrate Materials for Tissue-Engineered Medical Products¹

This standard is issued under the fixed designation F 2027; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

 ϵ^1 Note—Table 1 was editorially corrected in June 2001.

1. Scope

- 1.1 This guide addresses material characteristics of raw or virgin materials in a nonfabricated form that will ultimately undergo additional processing into growth, support, or delivery vehicles for cells or biomolecules. This guide does not apply to packaged, sterilized, and finished tissue-engineered medical products.
- 1.2 The purpose of the guide is to assist the developer of tissue-engineered medical products to locate relevant existing standards and test methods and to provide guidance for interim use of materials for which a standard does not exist.

2. Referenced Documents

- 2.1 ASTM Standards:
- D 1763 Specification for Epoxy Resins²
- D 1898 Practice for Sampling of Plastics³
- E 1298 Guide for Determination of Purity, Impurities, and Contaminants in Biological Drug Products⁴
- F 67 Specification for Unalloyed Titanium for Surgical Implant Applications⁵
- F 451 Specification for Acrylic Bone Cement⁵
- F 560 Specification for Unalloyed Tantalum for Surgical Implant Applications⁵
- F 603 Specification for High-Purity Dense Aluminum Oxide for Surgical Implant Application⁵
- F 604 Specification for Silicone Elastomers Used in Medical Applications⁵
- F 624 Guide for Evaluation of Thermoplastic Polyurethane Solids and Solutions for Biomedical Applications⁵
- F 641 Specification for Implantable Epoxy Electronic Encapsulants⁵
- F 665 Classification for Vinyl Chloride Plastics Used in Biomedical Application⁵
- ¹ This guide is under the jurisdiction of ASTM Committee F04 on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee F04.42 on Tissue Characterization.
 - Current edition approved May 10, 2000. Published August 2000.
 - ² Annual Book of ASTM Standards, Vol 08.01.
 - ³ Discontinued: see 1997 Annual Book of ASTM Standards, Vol 08.01.
 - ⁴ Annual Book of ASTM Standards, Vol 11.05.
 - ⁵ Annual Book of ASTM Standards, Vol 13.01.

- F 702 Specification for Polysulfone Resin for Medical Applications⁵
- F 748 Practice for Selecting Generic Biological Test Methods for Materials and Devices⁵
- F 749 Practice for Evaluating Material Extracts by Intracutaneous Injection in the Rabbit⁵
- F 755 Specification for Selection of Porous Polyethylene for Use in Surgical Implants⁵
- F 756 Practice for Assessment of Hemolytic Properties of Materials⁵
- F 763 Practice for Short-Term Screening of Implant Materials⁵
- F 813 Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices⁵
- F 895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity⁵
- F 981 Practice for Assessment of Compatibility of Biomaterials for Surgical Implants with Respect to Effect of Materials on Muscle and Bone⁵
- F 997 Specification for Polycarbonate Resin for Medical Applications³
- F 1088 Specification for Beta-Tricalcium Phosphate for Surgical Implantation⁵
- F 1185 Specification for Composition of Ceramic Hydroxylapatite for Surgical Implants⁵
- F 1251 Terminology Relating to Polymeric Biomaterials in Medical and Surgical Devices⁵
- F 1425 Specification for Virgin Poly (L-lactic Acid) Resin for Surgical Implants³
- F 1439 Guide for Performance of Lifetime Bioassay for the Tumorigenic Potential of Implant Materials⁵
- F 1472 Specification for Wrought Ti-6Al-4V Alloy for Surgical Implant Applications⁵
- F 1579 Specification for Polyaryletherketone (PAEK) Resins for Surgical Implant Applications⁵
- F 1581 Specification for Composition of Anorganic Bone for Surgical Implants⁵
- F 1634 Practice for In Vitro Environmental Conditioning of Polymer Matrix Composite Materials and Implant Devices⁵



- F 1635 Test Method for In Vitro Degradation testing of Poly (L-Lactic Acid) Resin and Fabricated Forms for Surgical Implants⁵
- F 1855 Specification for Polyoxymethylene Acetal for Medical Applications⁵
- F 1876 Standard Specification for Polyetherketoneetherketoneketone (PEKEKK) Resins for Surgical Implant Applications⁵
- F 1926 Test Method for Evaluation of the Environmental Stability of Calcium Phosphate Coatings⁵
- 2.2 Other Document:
- U.S. Pharmacopeia, Edition XXIII⁶
- 2.3 ISO Standards:⁷
- ISO 6474:1994 Implants for Surgery Ceramic Materials Based on Alumina
- ISO 10993-1, Biological Evaluation of Medical Devices— Part 1: Evaluation and testing
- ISO 10993-9—Part 9: Framework for identification and quantification of potential degradation products
- ISO 10993-12 Part 12: Sample preparation and reference materials
- ISO/DIS 10993-13 Part 13: Identification and quantification of potential degradation products from polymeric medical devices
- ISO/DIS 10993-14 Part 14: Identification and quantification of potential degradation products from ceramics
- ISO/DIS 10993-15—Part 15: Identification and quantification of potential degradation products from metals and alloys
- ISO/DIS 10993-17—Part 17: Methods for the establishment of allowable limits for leachable substances using health-based risk assessment
- ISO/CD 10993-18—Part 18: Chemical characterization of materials
- ISO/NWI 10993-19—Part 19: Physico-chemical, mechanical and morphological characterization of materials
- prEN 12442-1 Animal tissues and their derivatives utilized in the manufacture of medical devices—Part 1: Analysis and management of risk
- prEN 12442-2—Part 2: Controls on sourcing, collection and handling
- prEN 12442-3—Part 3: Validation of the elimination and/or inactivation of virus and transmissible agents
- ISO 111607 Product packaging
- 2.4 Code of Federal Regulations, Title 21, Part 820. Federal Register Vol. 43, No 141. July 21, 1978⁸

3. Terminology

- 3.1 Definitions:
- 3.1.1 *natural materials*, *n*—synthesized or produced by living cells.
- ⁶ Available from US Pharmacopia, Vol. 23 Mack Publishing Co., Easton, PA, 1005
- ⁷ Available from the American National Standards Institute, 25 W. 43rd St., 4th Floor, New York, NY 10036.
- ⁸ National Archives and Records Administration, 700 Pennsylvania Ave, NW, Washington, DC 20408.

3.1.2 *substrates*, *n*—raw or virgin materials that will ultimately be used in tissue-engineered medical products for growth, support, or delivery of cells or biomolecules.

4. Descriptive Chemical and Physical Information

- 4.1 The substrate material shall have specifications for an extensive set of chemical and physical properties such as, but not limited to, those listed in Table 1.
- 4.2 The necessary chemical and physical tests are a function of the class of material (for example, ceramic, polymer, metal, composite, or natural material). Each type of material has specific sets of properties to be specified. Natural polymers such as collagen or demineralized bone, and natural ceramics such as anorganic bone, are considered a subset of the polymers and ceramics categories respectively. The following AAMI, ISO, ASTM, and other recognized voluntary standards committee standards, include specific techniques for determining the chemical and physical properties listed in Table 1 and are suggested as guides for new standards development or for interim use for those materials without existing standards.
- 4.2.1 *Metals*—Specification F 1472, Specification F 560, Specification F 67, and ISO/DIS 10993-15 Part 15.
- 4.2.2 *Ceramics*, (for example, calcium phosphate, calcium carbonate, aluminum oxide, glasses) Specification F 603, Specification F 1088, Specification F 1185, Specification F 1581, Test Method F 1926, ISO 6474:1994, and ISO/DIS 10993-14 Part 14.
- 4.2.3 *Polymers*—Specification D 1763, Practice D 1898, Specification F 451, Specification F 604, Guide F 624, Specification F 641, Classification F 665, Specification F 702, Specification F 755, Specification F 997, Terminology F 1251, Specification F 1425, Specification F 1579, Practice F 1634, Test Method F 1635, Specification F 1855, Specification F 1876, and ISO/DIS 10993-13 Part 13.
- 4.2.4 Other General Test Methods—ISO/CD 10993-18—Part 18, ISO/NWI 10993-19—Part 19.
- 4.3 The following web site is suggested as an additional resource for relevant existing standards: www.fda.gov/cdrh/modact/recstand.html.

5. Sampling

5.1 It is suggested that the requirements shall be determined for each lot of the substrate material by sampling sizes and procedures in accordance with Practice D 1898 or some other equivalent.

TABLE 1

Chemical	Physical
Composition Purity Stability during storage Additives Trace elements	density molecular weight viscosity compresseion strength tension strength
Extractables (metals or solvents) Degradation kinetics Resorption kinetics Resorption kinetics Degradation products	elastic modulus fatigue strength yield strength hardness foreign particles structure - long range - short range



6. Handling, Packaging, and Labeling

 $6.1\,$ The product should be handled and packaged as specified in USP 661 or ISO 111607 and prEN 12442-2 — Part 2, and ISO 111607.

7. Quality Program Requirements

7.1 The manufacturer should conform to Quality Systems Regulations (see CFR 21, Part 820) or its equivalent.

8. Biocompatibility

8.1 Many materials have been shown to produce a well-characterized level of biological response following long-term clinical use in laboratory animals. When new applications of a

material, or modifications to the material or physical forms of the material, are being considered, then the recommendations and test methods of the following standards should be considered: Practice F 748, F 619, Practice F 749, Practice F 756, Practice F 763, Practice F 813, Practice F 981, and Guide F 1439-92 as well as Test Method F 895, ISO 10993-1, ISO/DIS 10993-9, Part 9, ISO/DIS 10993-17 - Part 17, prEN 12442-1 - Part 1, and prEN 12442-3 - Part 3.

9. Keywords

9.1 biomaterials; ceramics; composites; materials; metals; polymers; substrates; tissue-engineered medical products

ASTM International takes no position respecting the validity of any patent rights asserted in connection with any item mentioned in this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the risk of infringement of such rights, are entirely their own responsibility.

This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years and if not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standards and should be addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of the responsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you should make your views known to the ASTM Committee on Standards, at the address shown below.

This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959, United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the above address or at 610-832-9585 (phone), 610-832-9555 (fax), or service@astm.org (e-mail); or through the ASTM website (www.astm.org).